Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase 3 trials (BRAVE-AA1 and BRAVE-AA2)
Article full text
The above video abstract and plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2023